Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rusconi, S.
Right arrow Articles by Galli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rusconi, S.
Right arrow Articles by Galli, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 427-429
© 2002 The British Society for Antimicrobial Chemotherapy

Correspondence

Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects

Stefano Rusconi,*, Elisabetta Bulgheroni, Simona La Seta Catamancio, Francesco Croce, Mirko Lo Cicero, Paola Citterio and Massimo Galli

Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy

Sir,

Reverse transcriptase (RT) and protease (PRO) are the major target of antiretroviral compounds currently employed in HIV-1-infected individuals.1 Multiple-drug combinations with agents active against both enzymes show more benefits than monotherapy, as witnessed by a decrease in plasma HIV-1 RNA levels and an increase in CD4 cell counts.2 However, even following combination therapies with several drugs . . . [Full Text of this Article]

Acknowledgements

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?